Literature DB >> 8953064

Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality.

M B Edmond1, J F Ober, J D Dawson, D L Weinbaum, R P Wenzel.   

Abstract

Previous studies have shown that bacteremia due to vancomycin-resistant Enterococcus species (VRE) is associated with mortality of 17%-100%, but comorbid conditions may have confounded the estimates. We designed a historical cohort study to determine the mortality attributable to VRE bacteremia. Twenty-seven patients with VRE bacteremia were identified as cases. Within 7 days of the onset of bacteremia, severe sepsis developed in 12 patients (44%) and septic shock developed in 10 (37%). Case patients were closely matched to control patients without VRE bacteremia (1:1) by time of hospitalization, duration of exposure, underlying disease, age, gender, and surgical procedure. The mortality was 67% among cases and 30% among matched controls (P = 0.1). Thus, the mortality attributable to VRE bacteremia was 37% (95% confidence interval [CI], 10%-64%) and the risk ratio for death was 2.3 [CI, 1.2-4.1). We conclude that VRE bacteremia is associated with high rates of severe sepsis and septic shock. The attributable mortality approaches 40%, and patients who have VRE bacteremia are twice as likely to die than closely matched controls.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8953064     DOI: 10.1093/clinids/23.6.1234

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  49 in total

1.  Molecular epidemiology of vancomycin-resistant Enterococcus faecium in a large urban hospital over a 5-year period.

Authors:  W E Bischoff; T M Reynolds; G O Hall; R P Wenzel; M B Edmond
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

2.  In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.

Authors:  H W Boucher; C B Wennersten; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

Review 3.  Drug resistance in intensive care units.

Authors:  W C Albrich; M Angstwurm; L Bader; R Gärtner
Journal:  Infection       Date:  1999       Impact factor: 3.553

Review 4.  What action should be taken to prevent spread of vancomycin resistant enterococci in European hospitals?

Authors:  Ben Ridwan; Ellen Mascini; Netty van Der Reijden; Jan Verhoef; Marc Bonten
Journal:  BMJ       Date:  2002-03-16

Review 5.  Relationships between enterococcal virulence and antimicrobial resistance.

Authors:  L M Mundy; D F Sahm; M Gilmore
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 6.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

7.  Antimicrobial resistance takes another step forward.

Authors:  James Maskalyk
Journal:  CMAJ       Date:  2002-08-20       Impact factor: 8.262

8.  Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin.

Authors:  Issam I Raad; Hend A Hanna; Ray Y Hachem; Tanya Dvorak; Rebecca B Arbuckle; Gassan Chaiban; Louis B Rice
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

9.  Residual attributable mortality, a new concept for understanding the value of antibiotics in treating life-threatening acute infections.

Authors:  Richard P Wenzel; Chris Gennings
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

10.  Colonization with Multi-Drug Resistant Organisms in Nursing Homes: Scope, Importance, and Management.

Authors:  Marco Cassone; Lona Mody
Journal:  Curr Geriatr Rep       Date:  2015-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.